

Global Cancer Peptide Drug Market Opportunity, Approved Drug Dosage, Price, Sales & Clinical Trials Insight 2031

<https://marketpublishers.com/r/G6E0EBEE011CEN.html>

Date: June 2026

Pages: 800

Price: US\$ 3,000.00 (Single User License)

ID: G6E0EBEE011CEN

Abstracts

Global Cancer Peptide Drug Market Opportunity, Approved Drug Dosage, Price, Sales & Clinical Trials Insight 2031 Report Finding & Highlights:

Research Methodology

Global Cancer Peptide Drug Market Opportunity: > USD 25 Billion By 2031

Global & Regional Market trends Insight

Insight On Cancer Peptides In Clinical Trials: > 240 Drugs

Cancer Peptide Clinical Trials Insight By Company, Country, Indication & Phase

Number Of Approved Cancer Peptides: > 30 Drugs

Insight On Approved Cancer Peptide By Brand Name, Indication, Company, Location, Collaborations

Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis

Venom Peptides As New Opportunity For Cancer Peptide Therapy

Need For Peptide Therapeutics In Cancer Treatment & Why This Report?

Global Cancer Peptide Drug Market Opportunity, Approved Drug Dosage, Price, Sales & Clinical Trials Insight 20...

Global cancer peptide therapeutics market has transformed itself into a scientifically diverse yet active clinical field in cancer drug development due to its highly desirable potential for molecularly targeted and versatile cancer treatment modalities. Peptides hold a key position as they can be rationally designed to target and modulate complex cancer biology: receptor signaling pathways, intracellular protein interactions, cancer immune system targeting, and delivery to the tumor environment. As such, they represent a significant aspect of the next generation oncology research and development market.

In this report, we undertake a comprehensive analysis of global cancer peptide therapeutics market, highlighting clinical development efforts, partnership and collaboration activities, investment trends, and the development of novel scientific avenues, all aimed at assisting investors, pharmaceutical companies and stakeholders make their decision in the cancer treatment landscape with an effective use of peptide based innovative approaches.

Clinical Development Insight Included In Report

The report offers an extensive analysis of current oncology programs involving peptides at various levels of clinical development, starting with the first human studies to advanced stages and even registration studies, as well as the further assessment of already existing peptide therapies. The scope of clinical trials covers various cancer types, both commonly encountered and quite rare ones, thus demonstrating the increasing importance of peptide based solutions in oncology treatment.

The analysis also covers the important characteristics of these clinical trials, including whether monotherapy or combinations were used, targeted patient populations, lines of therapy, routes of administration, clinical trial designs, sponsoring organizations, development partners, and licensing agreements. The report also provides an assessment of the results achieved in terms of efficacy and safety from clinical trials using peptides in oncology therapies, specifically focusing on the percentage of responders, progression free survival rates, and overall survival figures. It further evaluates the potential for peptides to be used in combination therapies with chemotherapy, immunotherapies, and other antineoplastic treatments.

Major Companies Driving Peptide Therapeutics R&D

In this regard, the peptide oncology landscape includes strong contributions from big

pharma companies as well as small biotechnology firms. In particular, significant involvement of companies like Eli Lilly and Novartis in peptide based approaches through licensing, partnerships, and radioligand development programs can be observed. Peptide based techniques are currently used by these companies in the framework of their comprehensive oncology pipelines as part of combination approaches or targeted treatment strategies for a wide variety of cancers.

Additionally, smaller biotechnology companies like Avacta Therapeutics and Gate2Brain have been actively developing promising peptide based anticancer compounds in preclinical and clinical studies. Such companies have been collaborating with more mature players on translating novel peptides into treatment candidates within the field. The involvement of big pharma in this field, together with the innovative efforts of emerging biotechnology firms, ensures ongoing progress in peptide oncology.

Report Indicating Future Development Of Cancer Peptide Therapeutics

This report outlines an organized assessment of the ongoing development of peptide therapies against cancer, detailing developments from early research programs through to clinical trials and even to later stage validation studies. Peptides continue to demonstrate increasing utility in targeting multiple cancers, ranging from more common solid cancers to some of the rarer forms. One particular area of interest is the use of synthetic peptides in targeting protein–protein interactions within the cell and oncogenic signal transduction pathways involved in driving tumor proliferation and survival.

Moreover, developments in tumor penetration and delivery of peptides in cancer are noted, along with efforts towards improving selectivity within the tumor environment without causing toxicity to other parts of the body. In addition, developments in the peptide based immunotherapy approaches, including those targeting T-cell proliferation and stimulation, have been discussed, alongside peptide guidance of radiopharmaceuticals to tumors. Overall, this shows a wide range of ongoing progress in the field of peptide therapy in oncology

Contents

1. INTRODUCTION TO PEPTIDE THERAPEUTICS

- 1.1 Overview Of Peptide Therapeutics
- 1.2 Classification Of Anticancer Peptides
- 1.3 Designing & Functioning of Peptide Drugs
- 1.4 Significance Of Peptides As Cancer Therapeutics
- 1.5 Role of Peptides in Cancer Immunotherapy

2. DIFFERENT APPROACHES OF PEPTIDES IN CANCER THERAPEUTICS

- 2.1 Hormonal Peptides
- 2.2 Peptide Based Radionuclide Drug Carriers
- 2.3 Peptide Vaccines
- 2.4 Cytotoxic Drug Carriers
- 2.5 Anticancer Peptides
- 2.6 Tumor-Targeting and Cell-Penetrating Peptides
- 2.7 Peptide Nanomedicines
- 2.8 Receptor Antagonist and PPI-Modulating Peptides
- 2.9 Emerging Approaches

3. GLOBAL CANCER PEPTIDE DRUG MARKET INSIGHT

- 3.1 Current Market Scenario
- 3.2 Future Market Opportunities

4. CANCER PEPTIDE RESEARCH & MARKET TRENDS BY COUNTRY

- 4.1 US
- 4.2 China
- 4.3 Europe
- 4.4 Canada
- 4.5 UK
- 4.6 Australia
- 4.7 Japan
- 4.8 South Korea
- 4.9 India
- 4.10 Middle East

4.11 Latin America

5. CANCER PEPTIDE RESEARCH & MARKET TRENDS BY INDICATION

- 5.1 Breast Cancer
- 5.2 Hematological Malignancies
- 5.3 Urothelial Cancer
- 5.4 Prostate Cancer
- 5.5 Lung Cancer
- 5.6 Skin Cancer
- 5.7 Gastrointestinal Cancer
- 5.8 Gynecological Cancer
- 5.9 CNS Cancers

6. MARKETED CANCER PEPTIDES DRUGS & GENERICS INSIGHT – AVAILABILITY, COST, DOSAGE, INDICATION & PATENT INSIGHT

- 6.1 Firmagon (Degarelix)
- 6.1 Eligard (Leuprolide)
- 6.2 Lupron (Leuprolide Acetate)
- 6.3 Gonax (Degarelix Acetate)
- 6.4 Trelstar (Triptorelin)
- 6.5 Decapeptyl/Decapeptyl DR (Tryptorelin Acetate or Pamoate)
- 6.6 Velcade (Bortezomib)
- 6.7 Ninlaro (Ixazomib)
- 6.8 Kyprolis (Carfilzomib)
- 6.9 Istodax (Romidepsin)
- 6.10 Zoladex (Goserelin)
- 6.11 Cosmegen (Dactinomycin)
- 6.12 Somatuline Depot (Lanreotide)
- 6.13 Sandostatin/ Sandostatin LAR (Octreotide Acetate)
- 6.14 Bynfezia Pen (Octreotide)
- 6.15 Lutathera (Lutetium Lu 177 dotatate)
- 6.16 Mepact (Mifamurtide)
- 6.17 Netspot (Gallium Ga 68 dotatate)
- 6.18 Camcevi (Leuprolide)

7. MARKETED CANCER PEPTIDES DRUGS SALES INSIGHT

- 7.1 Kyprolis
- 7.2 Zoladex
- 7.3 Lutathera
- 7.4 Sandostatin
- 7.5 Somatuline
- 7.6 Decapeptyl SR
- 7.7 Ninlaro
- 7.8 Velcade
- 7.9 Lupron

8. GLOBAL PEPTIDE CANCER DRUGS CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE

- 8.1 Research
- 8.2 Preclinical
- 8.3 Phase
- 8.4 Phase I
- 8.5 Phase I/II
- 8.6 Phase II
- 8.7 Phase II/III
- 8.8 Phase III
- 8.9 Preregistration
- 8.10 Registered

9. MARKETING PEPTIDE CANCER DRUGS CLINICAL INSIGHT BY COMPANY, COUNTRY & INDICATION

10. VENOM PEPTIDES: NEW ERA FOR CANCER PEPTIDE THERAPY

- 10.1 Bee Venom-Derived Peptides
- 10.2 Scorpion Venom-Derived Peptides
- 10.3 Snake Venom-Derived Peptides
- 10.4 Spider Venom-Derived Peptides
- 10.5 Cone Snail Venom-Derived Peptides

11. GLOBAL PEPTIDE CANCER DRUG MARKET DYNAMICS

- 11.1 Favorable Market Parameters & Opportunities
- 11.2 Commercialization Challenges & Strategic Solutions

12. THERAPEUTIC PEPTIDE TARGETS

- 12.1 Signal Transduction Pathways
- 12.2 Cell Cycle Regulators
- 12.3 Apoptosis/Cell-Death Modulators
- 12.4 Tumor Suppressor Targeting peptides
- 12.5 Transcription Factor-Targeting Peptides
- 12.6 DNA Repair Pathway Inhibitors
- 12.7 Anti-Angiogenic Peptides
- 12.8 Immunomodulatory Peptides
- 12.9 Membrane-Disrupting/Oncolytic Peptides

13. PEPTIDE DRUGS V/S CONVENTIONAL CANCER THERAPEUTICS

- 13.1 Peptide Therapeutics v/s Chemotherapy
- 13.2 Peptide Therapeutics vs Immunotherapies
- 13.3 Peptide Therapeutics vs Gene Therapy

14. COMPETITIVE LANDSCAPE

- 14.1 3B Pharmaceuticals
- 14.2 APIM Therapeutics
- 14.3 AsclepiX Therapeutics
- 14.4 Bicycle Therapeutics
- 14.5 Biohaven Labs
- 14.6 BrightPath Biotherapeutics
- 14.7 Bristol-Myers Squibb
- 14.8 Gnubiotics Sciences
- 14.9 IDP Pharma
- 14.10 Janux Therapeutics
- 14.11 Medikine
- 14.12 Modulation Therapeutics
- 14.13 Novartis
- 14.14 Oncopeptides
- 14.15 Parabilis Medicines
- 14.16 PeptiDream
- 14.17 Perspective Therapeutics
- 14.18 Pharm-Sintez

14.19 Sapience Therapeutics

14.20 Vigeo Therapeutics

List Of Figures

LIST OF FIGURES

Figure 1-1: Functional Role Of Peptides In The Human Body

Figure 1-2: Historical Timeline Of Peptide Therapeutics

Figure 1-3: Anticancer Peptides - Classification

Figure 1-4: Traditional Structure-Based Design Strategies Used In Peptide Drug Discovery

Figure 1-5: Peptides - Significance As Cancer Therapeutics

Figure 1-6: Peptides - Role In Cancer Immunotherapy

Figure 2-1: Hormonal Peptides In Cancer Therapy

Figure 2-2: GnRH Therapy Mechanism

Figure 2-3: Somatostatin-Based Targeted Therapy

Figure 2-4: GHRH-IGF Axis

Figure 2-5: Peptide Radiopharmaceutical Structure

Figure 2-6: Peptide-Based Radionuclide Drug Carriers

Figure 2-7: Theranostic Workflow

Figure 2-8: Peptide Vaccine Immunotherapy

Figure 2-9: Peptide-Based Drug Delivery In Cancer

Figure 2-10: Structural Classification Of Anticancer Peptides

Figure 2-11: Mechanistic Overview Of Anticancer Peptides

Figure 2-12: Functional Roles Of Tumor-Targeting Peptides & Cell-Penetrating Peptides In Cancer Therapy

Figure 2-13: Major Internalization Pathways Of Cell-Penetrating Peptides

Figure 2-14: Design Of Bifunctional Peptide Constructs

Figure 2-15: Activatable Cell-Penetrating Peptide Strategy

Figure 2-16: Integration Of Peptides & Nanotechnology For Precision Oncology

Figure 2-17: Classification Of Receptor Antagonist & PPI-Modulating Peptides

Figure 2-18: Inhibition Of Oncogenic Protein-Protein Interactions

Figure 2-19: Modern Technologies For Peptide Discovery

Figure 2-20: Stabilization Of α -Helical Peptides By Stapling

Figure 2-21: Structural Advantages Of Cyclic Peptide Therapeutics

Figure 2-22: Foldamer-Based Mimics Of Protein Secondary Structures

Figure 2-23: Artificial Intelligence-Driven Next-Generation Peptide Design

Figure 3-1: Global – Peptide Therapeutic Market Size (US\$ Billion), 2024 - 2031

Figure 3-2: Global – Peptide Oncology Drugs Market Size (US\$ Billion), 2024 - 2031

Figure 3-3: Global Cancer Peptide Therapeutics Market – Future Opportunities

Figure 5-1: 17-328 Phase 1 (NCT03362060) Study – Initiation & Completion Year

Figure 5-2: TH1902-CTR-0001 Phase 1 (NCT04706962) Study – Initiation & Completion Year

Figure 5-3: PQ203-001 Phase 1 (NCT07190469) Study – Initiation & Completion Year

Figure 5-4: NCI-2014-02621 Phase 1 (NCT02334865) Study – Initiation & Completion Year

Figure 5-5: 20190675 Phase 1 (NCT04365179) Study – Initiation & Completion Year

Figure 5-6: BT5528-100 Phase 1/2 (NCT04180371) Study – Initiation & Completion Year

Figure 5-7: 202412028 Phase 1 (NCT06529822) Study – Initiation & Completion Year

Figure 5-8: PRMC 20-027 Phase 1 (NCT05010200) Study – Initiation & Completion Year

Figure 5-9: TB001 Version 2.1_2024-10-25 Phase 1/2 (NCT06400160) Study – Initiation & Completion Year

Figure 5-10: RAD301.2022-001 Phase 1 (NCT05799274) Study – Initiation & Completion Year

Figure 5-11: CFXX489A12101 Phase 1 (NCT06562192) Study – Initiation & Completion Year

Figure 5-12: CGCJ904A12101 Phase 1 (NCT07261631) Study – Initiation & Completion Year

Figure 5-13: NCI-2017-01781 Phase 1 (NCT03300817) Study – Initiation & Completion Year

Figure 5-14: TH1902-CTR-0001 Phase 1 (NCT04706962) Study – Initiation & Completion Year

Figure 5-15: NeoLIPA Phase 2 (NCT06651151) Study – Initiation & Completion Year

Figure 5-16: KEYNOTE-D18 Phase 3 (NCT05155254) Study – Initiation & Completion Year

Figure 5-17: ST316-101 Phase 1 (NCT05848739) Study – Initiation & Completion Year

Figure 5-18: FOG-001-101 Phase 1/2 (NCT05919264) Study – Initiation & Completion Year

Figure 5-19: RYZ801-101 Phase 1/2 (NCT06726161) Study – Initiation & Completion Year

Figure 5-20: AMPLIFY-7P Phase 1/2 (NCT05726864) Study – Initiation & Completion Year

Figure 5-21: CDMRP-CA170223 Phase 2 (NCT03796884) Study – Initiation & Completion Year

Figure 5-22: TH1902-CTR-0001 Phase 1 (NCT04706962) Study – Initiation &

Completion Year

Figure 5-23: CBX-12-201 Phase 2 (NCT06315491) Study – Initiation & Completion Year

Figure 5-24: BT5528-100 Phase 1/2 (NCT04180371) Study – Initiation & Completion Year

Figure 5-25: RAD301.2022-001 Phase 1 (NCT05799274) Study – Initiation & Completion Year

Figure 5-26: NCI-2015-00694 Phase 2 (NCT02455557) Study – Initiation & Completion Year

Figure 5-27: INTERCEPT-H3 Phase 1 (NCT04808245) Study – Initiation & Completion Year

Figure 5-28: ViCTOry Phase 1 (NCT05609994) Study – Initiation & Completion Year

Figure 5-29: NeoVax Phase 1 (NCT02287428) Study – Initiation & Completion Year

Figure 5-30: PRiME Phase 1 (NCT03299309) Study – Initiation & Completion Year

Figure 5-31: ST101-101 Phase 1/2 (NCT04478279) Study – Initiation & Completion Year

Figure 6-1: Firmagon – Patent Issue & Expiration Years

Figure 6-2: Firmagon – Price Per Unit & Supply Of Powder For Subcutaneous Injection (US\$), June'2026

Figure 6-3: Firmagon - Starting & Maintenance Dosage (mg)

Figure 6-4: Firmagon – Treatment Costs Of Initial Cycle & Maintenance Cycle (US\$), June'2026

Figure 6-5: Eligard - Cost Of Subcutaneous Powder For Injection By Dose (US\$), June'2026

Figure 6-6: Eligard – Recommended Dosage For Prostate Cancer On Monthly Basis (mg)

Figure 6-7: Eligard – Prostate Cancer Annual Treatment Cost By Dose (US\$), June'2026

Figure 6-8: Lupron Sustained Release Preparation – Patent Issue & Expiration Year

Figure 6-9: Lupron – Price Of Lupron Depot Intramuscular Kits (US\$), June'2026

Figure 6-10: Lupron – Price of Lupron Depot Intramuscular Powder By Dose (US\$), June'2026

Figure 6-11: Lupron – Annual Treatment Costs By Intramuscular Kit Dose (US\$), June'2026

Figure 6-12: Lupron – Annual Treatment Costs By Intramuscular Powder Dose (US\$), June'2026

Figure 6-13: Gonax - Cost of Supply Of Powder For Subcutaneous Injection (US\$), June'2026

Figure 6-14: Gonax - Starting & Maintenance Dosage (mg)

Figure 6-15: Trelstar – Patent Issue & Expiration Year

Figure 6-16: Trelstar - Cost Per Unit & Supply Of Powder For Intramuscular Injection (US\$), June'2026

Figure 6-17: Trelstar – Annual Treatment Cost By Dose (US\$), June'2026

Figure 6-18: Decapeptyl SR – Price For A Supply of 3mg, 11.25mg & 22.5mg Powder For Injection (GBP/US\$), June'2026

Figure 6-19: Decapeptyl SR - Recommended Dosage For Prostate Cancer (mg/week)

Figure 6-20: Decapeptyl SR - Annual Prostate Cancer Treatment Cost By Dose (US\$), June'2026

Figure 6-21: Velcade – Price Of 3.5 mg Powder For Injection (US\$), June'2026

Figure 6-22: Bortizomib – Price Of Injectable Powder For Injection By Dose (US\$), June'2026

Figure 6-23: Ninlaro – Patent Issue & Expiration Year

Figure 6-24: US & EU – Price Per Unit & Supply Of Ninlaro Capsule (US\$), June'2026

Figure 6-25: Ninlaro – Recommended Dose & Dose Reductions For Multiple Myeloma Treatment (mg/week)

Figure 6-26: Kyprolis – Price Of 10mg, 30mg & 60mg Intravenous Powder For Injection (US\$), June'2026

Figure 6-27: Kyprolis – Initial Dose & Maintenance Dose For Multiple Myeloma Treatment (mg/m²/week)

Figure 6-28: Kyprolis - Initial Dose & Maintenance Dose As Monotherapy For Multiple Myeloma Treatment (mg/m² Twice a Week)

Figure 6-29: Romidepsin – FDA Approval Year By Indication

Figure 6-30: Istodax & Romidepsin – Price Per Supply Of Intravenous Powder (US\$), June'2026

Figure 6-31: Zoladex - Cost Of Implant By Dose (US\$), June'2026

Figure 6-32: Zoladex – Recommended Dose For Prostate Cancer Management On Monthly Basis (mg/week)

Figure 6-33: Zoladex – Annual Treatment Cost Using 3.6mg & 10.8mg Implant (US\$), June'2026

Figure 6-34: Dactinomycin – Price For Generic & Branded 0.5 mg Powder For Injection (US\$), June'2026

Figure 6-35: Somatuline Depot – Price Per Unit & supply of Subcutaneous Solution By Dose (US\$), June'2026

Figure 6-36: Lanreotide – Price Per Unit & Supply Of Subcutaneous Solution (US\$), June'2026

Figure 6-37: Somatuline Depot – Treatment Cost Of 1 Cycle & Annual Treatment Cost of GEP-NETs & Carcinoid Syndrome (US\$), June'2026

Figure 6-38: Sandostatin – Price Per Unit & 10-Vial Supply By Dose (US\$), June'2026

Figure 6-39: Sandostatin LAR – Price Of Intramuscular Powder For Injection By Dose (US\$), June'2026

Figure 6-40: Octreotide – Price Per Unit & Supply Of 10 mL Injectable Solution (US\$), June'2026

Figure 6-41: Octreotide – Price Per Unit & Supply Of 5 mL Injectable Solution (US\$), June'2026

Figure 6-42: Octreotide – Price Per Unit & Supply Of Intramuscular Powder For Injection By Dose (US\$), June'2026

Figure 6-43: Sandostatin - Mean Initial Dose For Treatment Of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg/day)

Figure 6-44: Bynfezia Pen – Patent Issue & Expiration Year

Figure 6-45: Bynfezia Pen – Price Per Unit & Supply Of Subcutaneous Solution (US\$), June'2026

Figure 6-46: Bynfezia Pen – Mean Dose For First 2 Week & Subsequent Weeks (mcg/day)

Figure 6-47: Lutathera – Patent Issue & Expiration Years

Figure 6-48: Lutathera – RDP & ODE Regional Expiry Years

Figure 6-49: Mepact - Recommended Number Of Dose Administration/Week for 12 & 24 Weeks Treatment

Figure 7-1: Kyprolis – Global Sales (US\$ Million), 2020-2026

Figure 7-2: Kyprolis – Global Sales By Region (US\$ Million), Q1'2026

Figure 7-3: Kyprolis – Global Sales By Region (US\$ Million), 2025

Figure 7-4: Kyprolis - US Annual Sales (US\$ Million), 2020-2026

Figure 7-5: Kyprolis - ROW Annual Sales (US\$ Million), 2020-2026

Figure 7-6: Zoladex - Global Sales (US\$ Million), 2020-2026

Figure 7-7: Zoladex - Global Sales By Region (US\$ Million), Q1'2026

Figure 7-8: Zoladex - Global Sales By Region (US\$ Million), 2025

Figure 7-9: Zoladex - US Annual Sales (US\$ Million), 2020-2026

Figure 7-10: Zoladex – Europe Annual Sales (US\$ Million), 2020-2026

Figure 7-11: Zoladex – Emerging Markets Annual Sales (US\$ Million), 2020-2026

Figure 7-12: Zoladex - ROW Annual Sales (US\$ Million), 2020-2026

Figure 7-13: Lutathera - Global Sales (US\$ Million), 2020-2026

Figure 7-14: Lutathera - Global Sales By Region (US\$ Million), 2024–2026

Figure 7-15: Lutathera – Global Quarterly Sales (US\$ Million), Q1-Q4'2025

Figure 7-16: Lutathera - US Quarterly Sales (US\$ Million), Q1-Q4'2025

Figure 7-17: Lutathera - ROW Quarterly Sales (US\$ Million), Q1-Q4'2025

Figure 7-18: Sandostatin - Global Sales (US\$ Million), 2020-2026

Figure 7-19: Sandostatin - Global Quarterly Sales (US\$ Million), Q1-Q4'2025

Figure 7-20: Sandostatin - US Annual Sales (US\$ Million), 2020-2026
Figure 7-21: Sandostatin - US Quarterly Sales (US\$ Million), Q1-Q4'2025
Figure 7-22: Sandostatin - ROW Annual Sales (US\$ Million), 2020-2026
Figure 7-23: Sandostatin - ROW Quarterly Sales (US\$ Million), Q1-Q4'2025
Figure 7-24: Somatuline – Global Sales (US\$ Million), 2020-2026
Figure 7-25: Somatuline - Global Quarterly Sales (US\$ Million), Q1-Q4'2025
Figure 7-26: Somatuline – North America Sales (US\$ Million), 2022-2026
Figure 7-27: Somatuline - NA Quarterly Sales (US\$ Million), Q1-Q4'2025
Figure 7-28: Somatuline – Europe Sales (US\$ Million), 2022-2026
Figure 7-29: Somatuline - Europe Quarterly Sales (US\$ Million), Q1-Q4'2025
Figure 7-30: Somatuline – ROW Sales (US\$ Million), 2022-2026
Figure 7-31: Somatuline - ROW Quarterly Sales (US\$ Million), Q1-Q4'2025
Figure 7-32: Decapeptyl – Global Sales (US\$ Million), 2020-2026
Figure 7-33: Decapeptyl - Global Quarterly Sales (US\$ Million), Q1-Q4'2025
Figure 7-34: Decapeptyl – Europe Sales (US\$ Million), 2022-2026
Figure 7-35: Decapeptyl - Europe Quarterly Sales (US\$ Million), Q1-Q4'2025
Figure 7-36: Decapeptyl – ROW Sales (US\$ Million), 2022-2026
Figure 7-37: Decapeptyl - ROW Quarterly Sales (US\$ Million), Q1-Q4'2025
Figure 7-38: Ninlaro – Global Sales (US\$ Million), 2020-2026
Figure 7-39: Ninlaro - Global Quarterly Sales (US\$ Million), Q1-Q4'2025
Figure 7-40: Velcade - Global Sales (US\$ Million), 2020-2024
Figure 7-41: Velcade - Global Quarterly Sales (US\$ Million), Q1-Q4'2023
Figure 7-42: Global - Lupron Annual Sales (US\$ Million), 2019-2021
Figure 7-43: US - Lupron Annual Sales (US\$ Million), 2019-2021
Figure 7-44: ROW - Lupron Annual Sales (US\$ Million), 2019-2021

Figure 8-1: Global - Peptide Cancer Drug Clinical Pipeline by Phase (Number of Drugs), 2026

Figure 10-1: Venom-Derived Peptides In Cancer Therapy
Figure 10-2: Bee Venom-Derived Peptides In Cancer Therapy
Figure 10-3: Melittin - Mechanism Of Action
Figure 10-4: Scorpion Venom-Derived Peptides In Cancer Therapy
Figure 10-5: Hallmarks Of Cancer Targeted By Scorpion Venom Peptides
Figure 10-6: Snake Venom-Derived Peptides As Anticancer Agents
Figure 10-7: Spider Venom-Derived Peptides In Cancer Therapy
Figure 10-8: Nanotechnology-Enhanced Lycosin-I Therapy
Figure 10-9: Cone Snail Venom-Derived Peptides In Cancer Therapy

Figure 11-1: Global Peptide Cancer Drug Market - Drivers & Opportunities

Figure 11-2: Global Peptide Cancer Drug Market - Key Challenges & Corresponding Solutions

Figure 12-1: Classification & Molecular Targets of Anticancer Therapeutic Peptides

Figure 12-2: Therapeutic Peptide Targets In Cancer Signal Transduction Networks

Figure 12-3: Cell Cycle & Major Peptide Intervention Points

Figure 12-4: Checkpoint & Mitotic Targets For Therapeutic Peptides

Figure 12-5: Major Peptide Targets In Apoptosis Signaling

Figure 12-6: BH3 Mimetic Mechanism

Figure 12-7: Transcription Factor-Targeting Peptides In Cancer

Figure 12-8: Mechanisms Of Peptide Inhibition Of Transcription Factors

Figure 12-9: Dominant-Negative Peptide Strategy

Figure 12-10: Challenges & Solutions In Transcription Factor Peptide Therapy

Figure 12-11: DNA Damage Response & Sites Of Peptide Intervention

Figure 12-12: Synthetic Lethality In DNA Repair

Figure 12-13: Anti-Angiogenic Peptides – Examples

Figure 12-14: Anti-Angiogenic Peptides - Classification

Figure 12-15: Overall Mechanism Of Immunomodulatory Peptides

Figure 12-16: Dual Action Pathway

Figure 12-17: Membrane-Disrupting Peptides - Overall Mechanism

Figure 12-18: Cancer Selectivity Mechanism

List Of Tables

Table 1-1: Source Or Chemical Nature Of Early Peptides

Table 2-1: Classification Of Hormonal Peptide Therapeutics

Table 2-2: Major Receptor Targets For Peptide Radionuclide Delivery

Table 2-3: Types Of Peptide Cancer Vaccines

Table 2-4: Common Cytotoxic Payloads

Table 2-5: Types Of Peptide-Based Drug Delivery Systems

Table 2-6: Classification Of Cell-Penetrating Peptides

Table 2-7: Comparison Between TTPs & CPPs

Table 2-8: Stimuli-Responsive Peptide Nanomedicine Systems

Table 2-9: Nanocarrier Platforms In Peptide Nanomedicine

Table 2-10: Comparison Of Conventional Drug Delivery & Peptide Nanomedicine

Table 2-11: Peptide Engineering Strategies For PPI Inhibitors

Table 2-12: Types Of PPI-Modulating Peptides

Table 2-13: Comparison Of PPI-Modulating Peptides & Receptor Antagonist Peptides

Table 2-14: Limitations Addressed By Emerging Peptide Therapeutics

Table 2-15: Comparison Of Emerging Peptide Platforms

Table 2-16: Artificial Intelligence Tools In Peptide Design

Table 2-17: Advantages Of AI-Guided Peptide Discovery

Table 3-1: Global Cancer Peptide Therapeutics Market – Recent Fundings & Investments

Table 3-2: Global Cancer Peptide Therapeutics Market – Recent Collaborations

Table 6-1: Trelstar - Recommended Dose (mg/week)

Table 6-2: Velcade - Dosage Regimen For Patients With Previously Untreated Multiple Myeloma

Table 6-3: Kyprolis –Expiration Year Of Patents

Table 10-1: Broad Classification Of Venom Sources For ACPs

Table 10-2: Most Common Venom Sources Investigated For Anticancer Peptides

Table 10-3: Well-Known Venom-Derived Anticancer Peptides & Their Mechanisms

Table 10-4: Major Bee Venom Peptides & Their Anticancer Functions

Table 10-5: Major Scorpion Venom Peptides & Their Anticancer Activities

Table 10-6: Major Snake Venom-Derived Anticancer Peptides

Table 10-7: Major Spider Venom-Derived Anticancer Peptides

Table 10-8: Major Cone Snail Venom Peptides & Anticancer Activities

Table 12-1: MAPK Signaling Components Targeted By Therapeutic Peptides

Table 12-2: Major Signal Transduction Pathways & Their Cancer Functions

Table 12-3: Delivery & Engineering Strategies For Cell Cycle Peptides

Table 12-4: DNA Repair Targets & Therapeutic Outcomes

Table 12-5: Types Of Immunomodulatory Peptides

I would like to order

Product name: Global Cancer Peptide Drug Market Opportunity, Approved Drug Dosage, Price, Sales & Clinical Trials Insight 2031

Product link: <https://marketpublishers.com/r/G6E0EBEE011CEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6E0EBEE011CEN.html>